Summary financial statements

Summary financial statements
Summary consolidated income statement	2006 £m	Growth CER%	2005 £m
Turnover
Pharmaceutical	20,078	9	18,661
Consumer Healthcare	3,147	6	2,999
Total turnover	23,225	9	21,660
Cost of sales	(5,010)	6	(4,764)
Gross profit	18,215	9	16,896
Selling, general and administration	(7,257)	–	(7,250)
Research and development	(3,457)	11	(3,136)
Other operating income	307		364
Operating profit	7,808	17	6,874
Finance income	287		257
Finance costs	(352)		(451)
Share of after tax profits of associates and joint ventures	56		52
Profit before taxation	7,799	19	6,732
Taxation	(2,301)		(1,916)
Profit after taxation for the year	5,498	17	4,816
Profit attributable to minority interests	109		127
Profit attributable to shareholders	5,389		4,689
	5,498		4,816
Basic earnings per share (pence)	95.5p	19	82.6p
Diluted earnings per share (pence)	94.5p		82.0p

Summary consolidated balance sheet	2006 £m	2005 £m
Total non-current assets	14,561	14,021
Total current assets	10,992	13,177
Total assets	25,553	27,198
Total current liabilities	(7,265)	(9,511)
Total non-current liabilities	(8,640)	(10,117)
Total liabilities	(15,905)	(19,628)
Net assets	9,648	7,570
Shareholders’ equity	9,386	7,311
Minority interests	262	259
Total equity	9,648	7,570

Summary consolidated cash flow statement	2006 £m	2005 £m
Net cash inflow from operating activities	4,357	5,958
Net cash outflow from investing activities	(1,521)	(1,660)
Net cash outflow from financing activities	(4,792)	(2,914)
(Decrease)/increase in cash in the year	(1,956)	1,384
Exchange adjustments	(254)	233
Cash and bank overdrafts at beginning of year	3,972	2,355
Cash and bank overdrafts at end of year	1,762	3,972
Cash and bank overdrafts at end of year comprise:
Cash and cash equivalents	2,005	4,209
Overdrafts	(243)	(237)
	1,762	3,972

Summary consolidated income statement